Equities

Standard Chem & Pharm Co Ltd

1720:TAI

Standard Chem & Pharm Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)65.10
  • Today's Change0.300 / 0.46%
  • Shares traded172.31k
  • 1 Year change-0.15%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in TWD

The one analyst offering a 12 month price target expects Standard Chem & Pharm Co Ltd share price to fall to 48.00 in the next year from the last price of 65.10.
High-26.3%48.00
Med-26.3%48.00
Low-26.3%48.00

Earnings history & estimates in TWD

On Aug 06, 2024, Standard Chem & Pharm Co Ltd reported 2nd quarter 2024 earnings of 1.21 per share. This result exceeded the 1.14 expectation of the one analyst covering the company and under-performed last year's 2nd quarter results by 9.02%.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate+2.06%
Standard Chem & Pharm Co Ltd reported annual 2023 earnings of 4.67 per share on Feb 27, 2024.
Average growth rate+39.98%
More ▼

Revenue history & estimates in TWD

Standard Chem & Pharm CO., LTD. had 2nd quarter 2024 revenues of 1.76bn. This bettered the 1.65bn estimate of the one analyst covering the company. This was 17.89% above the prior year's 2nd quarter results.
Average growth rate+4.06%
Standard Chem & Pharm CO., LTD. had revenues for the full year 2023 of 6.24bn. Last year the company did not report any revenues.
Average growth rate+38.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.